---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-25-008137"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:28:42.433994+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioNexus files $100M shelf, enters $20M ATM with Maxim Group

## Summary
- Enters Equity Distribution Agreement with Maxim Group LLC to sell up to $20M of common stock via ATM.
- Filed S-3 shelf registration registering up to $100M of securities, not yet effective.
- Proceeds to support growth initiatives: term sheets with Fidelion Diagnostics (VitaGuard MRD) and BirchBioMed Inc.
- Company focuses on precision diagnostics, gene-based technologies in Asia and U.S.

## SEC filing metadata
- accession: 0001477932-25-008137
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793225008137/0001477932-25-008137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793225008137/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-25-008137
- JSON: https://secwatch.observer/filing/0001477932-25-008137.json
- Plain text: https://secwatch.observer/filing/0001477932-25-008137.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.